the relevance of the metabolites MT1 (N-tert-butyl-6-chloro-1,3,5-triazine-2,4-diamine), MT 13 (4-(tert-butylamino)-6-(ethylamino)-1,3,5-triazin-2-ol or 6-hydroxy-N2-ethyl-N4-tert-butyl-1,3,5-triazine-2,4-diamine), MT14 (4-amino-6-(tert-butylamino)-1,3,5-triazin-2-ol or N-tert-butyl-6-hydroxy-1,3,5-triazine-2,4-diamine), and of the unidentified metabolites LM1, LM2, LM3, LM4, LM5 and LM6 with respect to cancer, if terbuthylazine is classified under Regulation (EC) No 1272/2008 as ‘suspected of causing cancer’.
de relevantie van de metabolieten MT1 (N-tert-butyl-6-chloor-1,3,5-triazine-2,4-diamine), MT 13 (4-(tert-butylamino)-6-(ethylamino)-1,3,5-triazine-2-ol of 6-hydroxy -N2-ethyl-N4- tert-butyl-1,3,5-triazine-2,4-diamine), MT14 (4-amino-6-(tert-butylamino)-1,3,5-triazine-2-ol of N-tert-butyl-6-hydroxy-1,3,5-triazine-2,4-diamine), en van de ongeïdentificeerde metabolieten LM1, LM2, LM3, LM4, LM5 en LM6 ten aanzien van kanker, indien terbutylazine krachtens Verordening (EG) nr. 1272/2008 wordt ingedeeld als „verdacht van het veroorzaken van kanker”.